L19-IL-2, combined with rituximab and CTLA-4 blockade or L19-TNF immunocytokine, was able to completely eradicate β-cell lymphoma xenografts and demonstrated a substantial anti-tumor effect, even when used as a single agent. This evidence concerns the gene IL2 and neoplasm.